Sector: Life Sciences

Latest content

US Sanofi-Aventis precedent adds to toolbox for patentee prosecution and litigation success

The ruling by the US Court of Appeals for the Federal Circuit limits analogous art, and innovators can leverage this precedent by adopting certain patent drafting methods

23 May 2023

Five key takeaways from SCOTUS’ landmark Amgen v Sanofi enablement ruling

The Supreme Court yesterday handed down one of the most anticipated patent decisions in decades

19 May 2023

UPC central division will have branch in Milan, Italian government announces

But there’s no clarity yet on the new section’s competencies

19 May 2023

German court issues first ever AASI in life sciences case

The Munich Regional Court has also granted a permanent injunction against NanoString Technologies

18 May 2023

SCOTUS turns down much-watched ‘skinny label’ appeal in blow to generic drug companies

The decision, leaving in place a polarising Federal Circuit decision, has significant implications for life sciences IP strategies

16 May 2023

It is time for life sciences IP professionals to embrace change in the industry

Opinion: Pharma and biotech patent professionals must adapt to new challenges and opportunities

13 May 2023

Biogen’s European exclusivity boost is silver lining following US Tecfidera disaster

Following a catastrophic loss of exclusivity stateside, the company has received a boost in the EU

12 May 2023

Gilead scores major victory in controversial $1 billion dispute with US government

Delaware jury rules against the federal government in a big-money patent infringement suit being closely watched by policymakers.

11 May 2023

Amgen sues Sandoz as new wave of biosimilars disputes gains momentum

Following a lull in lawsuits, several new biologics have become the subject of litigation in recent months

05 May 2023

Moderna’s ongoing struggles over covid infringement liability have broader implications

The vaccine maker has suffered another setback, but its fight to deflect infringement responsibility to the US government continues

02 May 2023

Unlock unlimited access to all IAM content